4 citations
,
January 2001 in “Archives of Biochemistry and Biophysics” This study found that TPA induces apoptosis in pig renal epithelial cells by affecting cell cycle proteins, and activated ras can prevent this process.
1 citations
,
May 2013 in “Journal of the Egyptian Women's Dermatologic Society (Print)” This study found that increased PSA levels in women with hyperandrogenism may serve as a diagnostic marker, comparable to free testosterone levels.
September 2011 in “Urology” This study aimed to estimate the value of urine prostate specific antigen (uPSA) as a marker for benign prostatic hyperplasia (BPH) but reported no new clinical findings.
April 2018 in “The Journal of urology/The journal of urology” This study identified several patient-specific factors that can predict both the likelihood of undergoing and failing a post-TURP void trial, aiding in the selection of candidates for immediate assessment.
August 2003 in “Oncology Times” This article discusses the considerations and challenges surrounding a proposed large-scale trial on testosterone-replacement therapy in older men and reports no new results.
This study found that serum PSA levels and %fPSA have limited diagnostic capability in distinguishing prostate cancer, suggesting a need for new, more specific and sensitive markers.
March 2026 in “Drug Testing and Analysis” This study observed that the degradation product PTeCA significantly increased in hair treated with oxidative cosmetics, suggesting it could be a reliable marker for detecting such treatments, with a proposed PTCA cut-off value using PTeCA as the gold standard.
April 2022 in “Indian Journal of Forensic Medicine & Toxicology” This study found that PSA concentrations in peripheral blood are related to androgen levels, suggesting that PSA is a valuable marker for diagnosing hyperandrogenism in women.
September 2010 in “European Urology Supplements” PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.
April 2022 in “Authorea (Authorea)” This study reports two cases where localized prostate cancer with low PSA levels was incidentally detected through CT scans performed for other medical reasons.
1 citations
,
April 2012 in “Informa Healthcare eBooks” Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.
September 2017 in “ics.org”
September 2009 in “European Urology Supplements” This study found that a 3 mm margin around the prostate CTV may be adequate if accompanied by frequent imaging, but superior-inferior displacements were notably greater than in other directions.
1 citations
,
October 2008 in “Urology” PSA levels help determine prostate size and guide treatment choices for benign prostatic hyperplasia.
September 2010 in “European Urology Supplements” Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.
18 citations
,
February 2019 in “Scientific Reports” This study found that TSA restored the hair-inductive capacity of skin-derived precursors in mice by enhancing BMP gene expression and signaling through histone acetylation.
1 citations
,
April 2008 in “Progrès en Urologie” Systematic end-of-trial biopsies are the most reliable way to assess outcomes.
11 citations
,
December 2002 in “Controlled Clinical Trials” This study suggests that simple absolute threshold monitoring rules for compliance using the biomarker DHT perform similarly to more complex methods in the Prostate Cancer Prevention Trial.
July 2014 in “Urologia Journal” This study concludes that the accuracy of PSA testing for prostate cancer diagnosis is not only maintained but may be increased when used alongside 5-alpha reductase inhibitors like finasteride and dutasteride.
25 citations
,
March 2004 in “Regulatory Toxicology and Pharmacology” Using testosterone-stimulated weanling rats can effectively replace castrated rats for anti-androgen testing, reducing animal stress.
February 2007 in “Lancet Oncology” This article discusses the implications of finasteride on serum PSA levels and questions the routine recommendation for prostate biopsy at specific PSA thresholds, urging reevaluation of prostate cancer detection methods; it reports no clinical results.
148 citations
,
April 2009 in “Molecular Pharmaceutics” This study reports that three synthesized PSMA-targeted radioimaging agents demonstrated high affinity and specific localization to prostate cancer tumors in a mouse model, highlighting their potential for cancer detection and monitoring.
October 2006 in “Urology” The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
11 citations
,
June 2020 in “Biomedicines” This study concluded that incorporating the percentage of free PSA and urinary markers improves the accuracy of determining the need for prostate biopsy.
46 citations
,
May 2011 in “Movement Disorders” This article contains additional supporting information available online but presents no new research findings.
November 2011 in “国际泌尿系统杂志” This study concluded that intraprostatic injection with drugs and high frequency thermotherapy was more effective for treating prostatitis after TURP than a combination of antibiotherapy, tamsulosin, and finasteride.
February 2006 in “Inpharma Weekly”
32 citations
,
April 2006 in “The Journal of Urology” Using finasteride with TIP extends time off period for prostate cancer patients.
March 2015 in “The Journal of Urology” This study observed that finasteride therapy reduced PSA levels by about 40% over a year in Chinese patients with benign prostatic hyperplasia, with varying effects based on baseline PSA levels.
1 citations
,
July 2016 in “Mağallaẗ Kulliyyaẗ al-ṭibb Baġdād” This study found that women with polycystic ovary syndrome had significantly higher levels of prostate-specific antigen, which positively correlated with testosterone levels, the LH/FSH ratio, and hirsutism severity.